Combinations May Combat PARP Resistance
Combining PARP inhibitors with another kind of agent may be key in overcoming resistance.
The implementation of PARP inhibitors is one of the most exciting additions to the treatment of gynecologic cancer, said Leslie M. Randall, MD, MAS, associate professor in the Division of Gynecologic Oncology at the University of California in Irvine.
However, many patients become resistant to the drugs and progress. Combinations, such as a PARP inhibitor plus an immunotherapy agent or PI3K inhibitor, are now being explored to overcome this resistance and lead to better outcomes.